News

France's Sanofi to acquire biotech firm Vicebio for $1.15 billion
French pharmaceuticals company Sanofi said on Tuesday it would acquire British private biotechnology firm Vicebio for a total ...
Verywell Health on MSN5h
The Best Time to Get an RSV Vaccine for Older Adults
The CDC recently updated RSV vaccine recommendations to include certain adults aged 50 and up. When is the best time to get ...
Fierce Biotech16h
Sanofi tightens grip on RSV, paying $1.15B upfront for Vicebio and boosting its pipeline beyond mRNA
Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing preclin | Sanofi has struck a deal to buy Vicebio ...
Sanofi Expands Respiratory Vaccine Portfolio With UK Biotech Buy
Sanofi acquires Vicebio for $1.15 billion, adding a next-gen RSV-hMPV vaccine and ‘Molecular Clamp' tech to strengthen its respiratory vaccine pipeline.
COVID, flu, RSV: How these common viruses are tracking this winter—and how to protect yourself
Winter is here, and with it come higher rates of respiratory illnesses. If you've been struck down recently with a sore ...
BioPharma Dive8h
Sanofi to acquire vaccine biotech in billion-dollar deal
The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV, ...